Oseltamivir

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
(New page: <applet load="" size="480" color="" frame="true" spin="on" Scene ="" align="right" caption="Oseltamivir, better known as Tamiflu, (____)"/> ===Better Known as: Tamiflu=== * Marketed...)
Line 5: Line 5:
* Drug Class: [[Neuraminidase]] Inhibitor
* Drug Class: [[Neuraminidase]] Inhibitor
* Date of FDA Approval:
* Date of FDA Approval:
-
* 2004 Sales:
+
* 2009 Sales: $3.1 Billion
* Importance:
* Importance:
* See [[Pharmaceutical Drugs]] for more information about other drugs and diseases.
* See [[Pharmaceutical Drugs]] for more information about other drugs and diseases.

Revision as of 11:14, 12 December 2010

Oseltamivir, better known as Tamiflu, ([[____]])

Drag the structure with the mouse to rotate

Better Known as: Tamiflu

  • Marketed By:
  • Major Indication: Influenza Infection
  • Drug Class: Neuraminidase Inhibitor
  • Date of FDA Approval:
  • 2009 Sales: $3.1 Billion
  • Importance:
  • See Pharmaceutical Drugs for more information about other drugs and diseases.

Mechanism of Action

Pharmacokinetics

Neuraminidase Inhibitor Pharmacokinetics
Parameter Zanamivir Oseltamivir
Tmax (hr) 1.25 1.5
Cmax (ng/ml) 31.6 57
Bioavailability (%) 2 75
Protein Binding (%) 10 42
T1/2 (hr) 3 3.2
AUC (ng/ml/hr) 185 204
Clearance (L/h) 54.1 18.8
Dosage (mg) 10 300
Metabolism None Hepatic

For References to Pharmacokinetic data, see: References

References


Proteopedia Page Contributors and Editors (what is this?)

David Canner, Eric Martz, Alexander Berchansky

Personal tools